Challenges of imaging interpretation to predict oligodendroglioma grade: a report from the Neuro-Oncology Branch
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Background: To illustrate challenges of imaging interpretation in patients with oligodendroglioma seen at a referral center and evaluate interrater reliability. Methods: Two neuro-oncologists reviewed diagnostic preradiation MRIs of oligodendroglioma patients; interrater reliability was calculated with the kappa coefficient (k). A neuroradiologist measured presurgical apparent diffusion coefficient (ADC), if available. Results: Extensive enhancement was noted in four of 58 patients, k = 0.7; necrosis in seven of 58, k = 0.61; calcification in seven of 17, k = 1.0; diffusion restriction in two of 39 patients, k = 1.0 (all only in grade 3). ADC values with receiver operator characteristic analysis for area under the curve were 0.473, not significantly different from the null hypothesis (p = 0.14). Conclusions: Extensive enhancement, necrosis and calcification correlated with grade 3 oligodendroglioma in our sample. However, interrater variability is an important limitation when assessing radiographic features, supporting the need for standardization of imaging protocols and their interpretation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2. Representative images from a patient with oligodendroglioma WHO grade 2 (A–D). MRI axial T1 with contrast, axial fluid-attenuated inversion recovery (FLAIR), and axial apparent diffusion coefficient (ADC) ([A], [B] and [C], respectively), showing a large left frontal mass with no obvious contrast enhancement, FLAIR hyperintensity and high ADC values. (D) Axial CT head without contrast showing left frontal hypodensity without definitive calcification.](https://figures.cochat.ai/paper-figures/d78004a09e9745998703627ba72ebc88/challenges-of-imaging-interpretation-to-predict-oligodendroglioma-grade-a-report-figure-2.jpg)
![Figure 3. Representative images from a patient with oligodendroglioma WHO grade 3 (A–D). MRI Axial T1 with contrast, axial fluid-attenuated inversion recovery (FLAIR), and axial apparent diffusion coefficient (ADC) ([A], [B] and [C], respectively) showing right frontotemporal mass with contrast enhancement, FLAIR hyperintensity, and mixture of low and high ADC values. (D) Axial CT scan head without contrast showing right frontal calcification (single arrow) and bi-frontal intracranial hemorrhage (double arrow).](https://figures.cochat.ai/paper-figures/f8259575a9de45cb9084e8d24ebf67bd/challenges-of-imaging-interpretation-to-predict-oligodendroglioma-grade-a-report-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the grading criteria in the current classification schema for oligodendrogliomas continues to predominantly rely upon histopathologic examination; the differentiating criterion between grade 2 and grade 3 oligodendrogliomas are the presence of conspicuous microvascular proliferation and/or 6 mitoses per 10 high-power field [3,4,5,6,7,8,9,10,11].”
From BPC 157 Therapy of Myotendinous Junction Injury in Rats (2025) · cites this paper as [3]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
The 2021 WHO classification of tumors of the central nervous system: a summary
Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab106 · Cited by 12,273
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Ostrom, Q. T., Cioffi, G., Gittleman, H., Patil, N., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz150 · Cited by 2,585
van den Bent, M., Afra, D., de Witte, O., Hassel, M. B., Schraub, S., Hoang-Xuan, K., Malmström, P.-O., Collette, L., Piérart, M., Mirimanoff, R., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67070-5 · Cited by 1,035
Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
(2015) · Neuro-Oncology · doi:10.1093/neuonc/nov095 · Cited by 663
Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma
Bettegowda, C., Agrawal, N., Jiao, Y., Sausen, M., Wood, L. D., Hruban, R. H., Rodriguez, F. J., Cahill, D. P., McLendon, R., Riggins, G., et al. (2011) · Science · doi:10.1126/science.1210557 · Cited by 553
Olar, A., Wani, K. M., Alfaro-Munoz, K. D., Heathcock, L. E., van Thuijl, H. F., Gilbert, M. R., Armstrong, T. S., Sulman, E. P., Cahill, D. P., Vera-Bolanos, E., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1398-z · Cited by 354
Self-citationPrognostic relevance of genetic alterations in diffuse lower-grade gliomas
Aoki, K., Nakamura, H., Suzuki, H., Matsuo, K., Kataoka, K., Shimamura, T., Motomura, K., Ohka, F., Shiina, S., Yamamoto, T., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox132 · Cited by 307
Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria
Daumas-Duport, C., Tucker, M.-L., Kolles, H., Cervera, P., Beuvon, F., Varlet, P., Udo, N., Koziak, M., & Chodkiewicz, J.-P. (1997) · Journal of Neuro-Oncology · doi:10.1023/a:1005759220434 · Cited by 216
Cited by
Joyner, D., Garrett, J., Batchala, P. P., Rama, B., Ravicz, J. R., Patrie, J. T., Lopes, M.-B., Fadul, C. E., Schiff, D., Jain, R., et al. (2022) · Neuroradiology · doi:10.1007/s00234-022-03038-0 · Cited by 32
Adult-type and Pediatric-type Diffuse Gliomas
Nafe, R., Porto, L., Samp, P.-F., You, S.-J., & Hattingen, E. (2023) · Clinical Neuroradiology · doi:10.1007/s00062-023-01277-z · Cited by 22
“High-grade oligodendrogliomas can also show focal necrosis [18, 19].”
BackgroundZhu, Q., Jiang, H., Cui, Y., Ren, X., Li, M., Zhang, X., Li, H., Shen, S., Li, M., & Lin, S. (2023) · European Radiology · doi:10.1007/s00330-023-10405-9 · Cited by 19
Rogers, J. L., Wall, T., Acquaye, A., Boris, L., Kim, Y., Aldape, K., Quezado, M., Butman, J. A., Smirniotopoulos, J. G., Chaudhry, H., et al. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04613-6 · Cited by 12
“…importance of referring patients to highly specialized neuro-oncology centers, which leverage advanced molecular testing as a complement to traditional histology, have rich experience in imaging interpretation [40], and incorporate a robust basic, translational, and clinical research program [41].”
Self-citationLee, D. Y., Choi, K. E., Han, K., Choi, S. H., Lee, N., Ahn, S. S., Chang, J. H., Kim, S. H., Lee, S., & Park, Y. W. (2024) · Neuroradiology · doi:10.1007/s00234-024-03430-y · Cited by 9
Metadata
- Authors
- Aboud, O., Shah, R., Vera, E., Burton, E., Theeler, B., Wu, J., Boris, L., Quezado, M., Reyes, J., Wall, K., R Gilbert, M., S Armstrong, T., & Penas-Prado, M.
- Affiliations
- National Cancer Institute (US)
- National Institutes of Health (US)
- Walter Reed National Military Medical Center (US)
- Neuro-Oncology Branch, Center for Cancer Research,National Cancer Institute, Bethesda, MD 20892, USA
- Venue
- CNS Oncology
- Publisher
- Informa UK Limited
- Published
- 2022-02-10
- Volume
- 11
- Issue
- 1
- Pages
- CNS83-CNS83
- ISSN
- 2045-0907 (ISSN-L)
- 2045-0915
- PMC
- PMC8988255
- OpenAlex
- W4211052852
- Cited by
- 10
- References
- 35
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 3 · 2022: 1
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- CNS Oncology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
- Funders
- the Cancer Moonshot funds and managed at the National Institutes of Health, National Cancer Institute, Center for Cancer Research, Neuro-Oncology Branch
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced Neuroimaging Techniques and Applications
- Keywords
- oligodendroglioma, tumor grade prediction, MRI interpretation, inter-rater reliability, apparent diffusion coefficient, tumor enhancement, tumor necrosis, calcification, restricted diffusion, imaging protocol standardization
- MeSH terms
- Brain Neoplasms, Humans, Oligodendroglioma, Retrospective Studies, Reproducibility of Results, Diffusion Magnetic Resonance Imaging, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Challenges of imaging interpretation to predict oligodendroglioma grade: a report from the Neuro-Oncology Branch. https://app.cochat.ai/papers/10.2217/cns-2021-0005
- The paper
- Aboud, O., Shah, R., Vera, E., Burton, E., Theeler, B., Wu, J., Boris, L., Quezado, M., Reyes, J., Wall, K., R Gilbert, M., S Armstrong, T., & Penas-Prado, M. (2022). Challenges of imaging interpretation to predict oligodendroglioma grade: a report from the Neuro-Oncology Branch. CNS Oncology. https://doi.org/10.2217/cns-2021-0005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.